Apart from the increased allocation, the central drug regulator has been strenghtened, a plan for building over 1,000 medical trial sites has been announced, and cancer medicines have been exempted from custom duties.
The DCGI has also mentioned in the notice that the quality of the injectables is required to be stored at 2-8 degrees Celsius; if not handled properly, storage quality might be compromised.
Speaking at the 19th International Conference of Drug Regulatory Authorities (ICDRA) INDIA-2024 on Wednesday, ICMR DG Dr Bahl said, "The handheld X-rays are available at a very high cost and now the IIT Kanpur in partnership with ICMR has developed a handheld X-ray indigenously which will
At 19th International Conference of Drug Regulatory Authorities (ICDRA) INDIA-2024, MoS Health Anupriya Patel on Wednesday said that new rules and regulatory introduced to bring medical advancement to match the expectation at global level.
The second day of the 19th International Conference of Drug Regulatory Authorities (ICDRA) workshop happening in Yashobhoomi Convention Centre, Dwarka, New Delhi, concluded on Tuesday. There were a number of technical presentations and moderated panel discussions on the regulatory framework
Union Health Minister JP Nadda on Monday inaugurated the 19th International Conference of Drug Regulatory Authorities and said that the ICDRA platform provides a space to share knowledge, foster partnerships and develop regulatory frameworks that ensure quality of medical products worldwi
Union Minister of Chemicals and Fertilisers JP Nadda, during his address at the 19th International Conference of Drug Regulatory Authorities (ICDRA), hailed India's crucial role during the Covid-19 pandemic and how the country is emerging as a global leader in health resilience and innovatio
As per senior official sources, the DCGI is actively taking action against manufacturing companies producing drugs that do not meet the required standards of quality (NSQ). This proactive approach aims to protect public health and maintain trust in the healthcare system.
The drug regulator suspended permission, citing the company's failure to respond to the queries on the product for which the DCGI says "no approval was granted."
The Drugs Controller General of India (DCGI) on Wednesday suspended the product PresVu produced by Entod Pharmaceuticals after the company failed to respond to the queries on the product for which the DGCI says no approval was granted.
These concerns regarding drug production were raised during the meeting of the Senate Standing Committee on National Health Services, Regulations and Coordination (SCNHSRC), chaired by Pakistani Senator Amir Waliuddin Chishti, at the Parliament House.